<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32154900</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1652-7518</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><PubDate><Year>2020</Year><Month>Mar</Month><Day>09</Day></PubDate></JournalIssue><Title>Lakartidningen</Title><ISOAbbreviation>Lakartidningen</ISOAbbreviation></Journal><ArticleTitle>[Quality of life the goal of care for patients with ALS].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">FX4H</ELocationID><Abstract><AbstractText>ALS is characterized by the degeneration of upper and lower motor neurons. In about 70% of patients with ALS the disease has an spinal onset, while about 30% of the patients have a bulbar onset.&#xa0; Cognitive dysfunction and behavioral changes are seen in about 50% of the patients, and 15% develop frontotemporal dementia.&#xa0; There is no single test that provides the ALS diagnosis. The diagnosis is based on clinical and electrophysiological signs, and the exclusion of other diseases. The only disease modulating treatment approved for ALS in Sweden is Riluzole, sadly only with limited effect. Other treatments are symptomatic and the goal is to help patients achieve the best possible quality of life through multidiciplinary ALS teams.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Karolinska Institutet - Institutionen f&#xf6;r klinisk neurovetenskap Stockholm, Sweden Karolinska Institute - Klinisk neurovetenskap Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nygren</LastName><ForeName>Ingela</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Uppsala Universitet Institutionen f&#xf6;r neurovetenskap - Uppsala, Sweden Uppsala Universitet Institutionen f&#xf6;r neurovetenskap - Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachau</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Karolinska Universitetssjukhuset - Stockholm, Sweden Clin of Neurology - karolinska Univ Hospital Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staaf</LastName><ForeName>Gert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Lunds Universitet - Neurologen Lund, Sweden Lunds Universitet - Neurologen Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>swe</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>God livskvalitet m&#xe5;let med v&#xe5;rd och omh&#xe4;ndertagande vid ALS - Enda sjukdomsmodifierande l&#xe4;kemedlet har begr&#xe4;nsad effekt.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Lakartidningen</MedlineTA><NlmUniqueID>0027707</NlmUniqueID><ISSNLinking>0023-7205</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006040" MajorTopicYN="N">Goals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32154900</ArticleId><ArticleId IdType="pii">FX4H</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>